Summary & Overview
HCPCS J0737: Clindamycin Injection (Baxter), 300 mg
HCPCS Level II code J0737 designates a 300 mg injection of clindamycin phosphate (Baxter), identified as not therapeutically equivalent to J0736. This code is used to report administration of a specific parenteral antibiotic product and is relevant across hospital, clinic, and ambulatory settings where intravenous or intramuscular antibiotics are delivered. Precise coding of product-specific injectable drugs matters nationally for clinical documentation, inventory management, and payer adjudication.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for using a product-specific clindamycin injection, the typical sites of service where it is billed, and what to expect in payer coverage patterns. The publication highlights common billing considerations such as the need to use the specified HCPCS Level II code for the Baxter product and notes that J0737 is distinct from other clindamycin codes.
The report provides benchmarks and policy-relevant information where available, summarizes common modifiers and service-line implications, and identifies gaps where input data was not provided. Data not available in the input is clearly indicated in relevant sections.
Billing Code Overview
HCPCS Level II code J0737 describes an injection of clindamycin phosphate (Baxter), 300 mg, specifically noted as not therapeutically equivalent to J0736. The code represents a single-dose injectable antibiotic formulation of clindamycin used for treatment of susceptible bacterial infections.
-
Service type: Injectable antibiotic administration
-
Typical site of service: Hospital outpatient department, inpatient hospital setting, clinic, or other site where parenteral antibiotics are administered
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with a history of diabetic foot ulcer presents to an outpatient infusion center for administration of parenteral antibiotics after culture grew methicillin-sensitive Staphylococcus aureus susceptible to clindamycin. The patient recently failed oral therapy due to poor gastrointestinal absorption and has escalating local signs of infection with cellulitis and induration. The clinician orders an intramuscular or intravenous dose of J0737 (injection, clindamycin phosphate (Baxter), 300 mg). Nursing confirms allergy history (no clindamycin allergy), obtains baseline vital signs, and verifies venous access. The medication is prepared per pharmacy labeling and administered with observation for immediate hypersensitivity. Documentation includes indication, dose, route, lot number, NDC, start and stop times, patient tolerance, and any associated procedure codes for infusion or injection administration. If given during an emergency department visit, the encounter also includes evaluation and management coding for triage and decision-making. Typical workflow includes physician order, pharmacist verification, nursing administration, and documentation in the electronic health record with the appropriate modifier when clinically applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure |